Precision Biosciences (DTIL) Change in Receivables (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Change in Receivables of $4.0 million for Q1 2026, up 1877.78% year-over-year from $202247.2 in Q1 2025, and up 100100.0% quarter-over-quarter from -$4000.0 in Q4 2025.
Precision Biosciences (DTIL) Change in Receivables (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Change in Receivables for 9 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 1877.78% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 1135.23% YoY), while the FY2025 annual figure was -$229000.0, up 65.92% from the prior year.
- Change in Receivables improved to $4.0 million in Q1 2026 per DTIL's latest filing, from -$4000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $4.0 million in Q1 2026 and bottomed at -$49.8 million in Q3 2022.
- Historically, Change in Receivables has averaged -$3.1 million across 5 years, with a median of -$19000.0 in 2024.
- Annual changes were most pronounced in 2023 — Change in Receivables plunged 51940.0% — and 2026, when it surged 1877.78%.
- Precision Biosciences' Change in Receivables stood at $5000.0 in 2022, then slumped by 51940.0% to -$2.6 million in 2023, then jumped by 101.58% to $41000.0 in 2024, then sank by 109.76% to -$4000.0 in 2025, then soared by 100100.0% to $4.0 million in 2026.
- Business Quant data shows DTIL's Change in Receivables at $4.0 million in Q1 2026, -$4000.0 in Q4 2025, and $4000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.00 Mn |
| Jun 30, 2026 | -4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Jun 30, 2025 | -4,000.00 |
| Jun 30, 2025 | -4,000.00 |
| Mar 31, 2025 | -225,000.00 |
| Mar 31, 2025 | -225,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Jun 30, 2024 | -183,000.00 |
| Jun 30, 2024 | -183,000.00 |
| Mar 31, 2024 | -511,000.00 |
| Mar 31, 2024 | -511,000.00 |